Lactobacillus gasseri ： Gastroesophageal Reflux Disease (GERD)
DEmerging evidence from Japanese studies. May reduce acid-related symptoms. Not yet replicated in Western populations.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dlactobacillus\u002Dgasseri\u0026condition\u003Dgerd';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
D
結論
Emerging evidence from Japanese studies. May reduce acid-related symptoms. Not yet replicated in Western populations.
Key Study Findings
Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None
vs: placebo
Outcome: improvement in key IBS symptoms
効果: None
None
対象集団: patients with IBS from 32 RCTs evaluating 10 probiotic strains
In Vitro
Lactobacillus gasseri suppresses the Helicobacter pylori-induced expression of the proliferation-associated factors HBEGF and TGF-α in …
Dose: None
vs: H. pylori infection without lactobacilli
Outcome: ADAM17, HBEGF, TGF-alpha expression
効果: None
None
対象集団: AGS gastric epithelial cells and mouse model
In Vitro
The modulatory effect of Lactobacillus gasseri ATCC 33323 on autophagy induced by extracellular vesicles of …
Dose: 50 μg/ml
vs: None
Outcome: Inflammatory markers
効果: None
None
対象集団: None
Other
Effect of Lactobacillus gasseri BIO6369 and Lacticaseibacillus rhamnosus BIO5326 on Gastric Carcinogenesis Induced by Helicobacter …
Dose: None
vs: None
Outcome: Inflammatory markers
効果: None
None
対象集団: Cancer patients
In Vitro
Effects of Glutamine, Curcumin and Fish Bioactive Peptides Alone or in Combination on Intestinal Permeability …
Dose: None
vs: None
Outcome: inflammation markers
効果: None
None
対象集団: Mice
Case-Control
n=178
Oral and gastric microbiome in relation to gastric intestinal metaplasia.
Dose: None
vs: None
Outcome: Oral/gastric microbiome associations with IM
効果: None
None
対象集団: Gastric intestinal metaplasia cases and matched controls
Key Statistics
3
研究数
300
参加者数
↑
Positive
D
グレード
Referenced Papers
Journal of clinical …
2026
International journal of …
2025
Microbial pathogenesis
2024
8 件の引用
Helicobacter
2024
5 件の引用
International journal of …
2023
9 件の引用
International journal of …
2022
59 件の引用
BMC microbiology
2022
28 件の引用
Food & function
2022
19 件の引用
Probiotics and antimicrobial …
2021
30 件の引用
Comparative immunology, microbiology …
2019
72 件の引用
BMJ open gastroenterology
2019
14 件の引用
Digestion
2017
67 件の引用
Gastroenterology research and …
2016
38 件の引用
Helicobacter
2015
26 件の引用
PloS one
2014
171 件の引用
Frontiers in microbiology
2014
78 件の引用
Genomic and phenotypic evidence for probiotic influences of Lactobacillus gasseri on human health.
Review
FEMS microbiology reviews
2013
196 件の引用
Journal of food …
2012
56 件の引用
Journal of clinical …
2012
37 件の引用
Letters in applied …
2010
126 件の引用
Journal of medicinal …
2010
19 件の引用
Probiotics and antimicrobial …
2010
9 件の引用
Helicobacter
2009
48 件の引用
Cellular microbiology
2006
50 件の引用
Letters in applied …
2006
26 件の引用
Journal of gastroenterology …
2003
77 件の引用
The Journal of …
2001
309 件の引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- general:
- 1-10 billion CFU/day
- gerdsupport:
- 1-5 billion CFU/day
- hpylorisupport:
- 100 million CFU/day (LG21 strain, yogurt form) for 8-12 weeks
上限量： Well-tolerated up to 10 billion CFU/day in clinical trials
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| 50 μg/ml | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Neutral | 178 |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
推奨摂取タイミング： Before meals or with meals; yogurt form taken with food
Safety & Side Effects
報告されている副作用
- ⚠ Mild gas during initial use
- ⚠ Occasional loose stools
- ⚠ Rare abdominal discomfort
- ⚠ Very rare: bacteremia in immunocompromised individuals
既知の相互作用
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Proton pump inhibitors (altered gastric pH may affect colonization)
- ● Immunosuppressants (theoretical risk in immunocompromised patients)
耐容上限摂取量： Well-tolerated up to 10 billion CFU/day in clinical trials
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does Lactobacillus gasseri help with Gastroesophageal Reflux Disease (GERD)?
Based on 3 studies with 300 participants, there is preliminary evidence that needs more research that Lactobacillus gasseri may support Gastroesophageal Reflux Disease (GERD) management. Our evidence grade is D (Very Early Research).
How much Lactobacillus gasseri should I take for Gastroesophageal Reflux Disease (GERD)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus gasseri?
Reported side effects may include Mild gas during initial use, Occasional loose stools, Rare abdominal discomfort, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus gasseri and Gastroesophageal Reflux Disease (GERD)?
We rate the evidence as Grade D (Very Early Research). This rating is based on 3 peer-reviewed studies with 300 total participants. The overall direction of effect is positive.
Related Evidence
に関する他の成分： Gastroesophageal Reflux Disease (GERD)
Lactobacillus gasseri 他の症状・状態について
FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。